Media centre

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG

Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

Medpace
24 February 2014

Cinven to invest in Medpace

Strong growth drivers in CRO market

European private equity firm, Cinven, today announces a majority investment in Medpace, Inc. (‘Medpace’ or ‘the Group’), a leading contract research organisation (‘CRO’), for a total consideration of US$915 million plus certain cash inflows relating to the period of ownership, acquired from CCMP Capital Advisors, LLC.

Medpace is a global CRO business providing management services to the R&D departments of pharma, biotech and medical device clients to help plan and oversee their clinical trials. The Group focuses on small to mid-size companies and has significant expertise in therapeutic areas such as metabolic, cardiovascular, oncology, anti-viral/anti-infective, central nervous system and medical devices.

Cinven’s healthcare team has been focused for some time on the CRO industry as an attractive market in which to invest. Increased R&D spend by the pharma and biotech industry, due to the growing number and complexity of clinical trials required to bring new molecules to market, is expected to fuel strong growth for the CRO industry, especially for those operators (like Medpace) that focus on smaller pharma and biotech customers, where the outlook for R&D spend is most positive.

In addition, Medpace has been rapidly expanding its presence in Europe and has the opportunity to achieve greater penetration across Europe and Asia, where Cinven has a strong track record of portfolio company growth.

Established in 1992, Medpace is headquartered in Cincinnati, Ohio and has global operations in over 45 countries. It has over 1,500 employees with approximately 40% of clinical operations employees in Europe. In 2013, Medpace generated an adjusted EBITDA of US$94m.

The management team will continue to be led by Dr. August Troendle, the founder of Medpace and current President and CEO. He formerly worked at Sandoz (Novartis) within clinical development and for the US Food and Drug Administration. Dr Troendle and the Medpace management team will remain significant minority investors alongside Cinven.

Supraj Rajagopalan, Partner at Cinven, said:
“Cinven’s healthcare team identified the CRO industry as an attractive market in which to invest given its fundamental growth characteristics. The CRO industry consolidation has created a gap in the market serving the mid-cap pharma and smaller biotech players – where Medpace operates and where we intend to capitalise on organic growth opportunities.”

Alex Leslie, Principal at Cinven, added:
“Medpace has a highly experienced management team and a strong market positioning, with growth in Europe and Asia presenting a real opportunity for the business. The Cinven team is well placed to accelerate this growth given our considerable European presence and also the strength of our Asia portfolio team – which has been instrumental in the success of international businesses in the region.”

Dr August Troendle, CEO, added:
“We are very excited about the opportunity of working with Cinven. Medpace has generated significant growth recently in Europe, so it made huge sense for us to partner with a private equity sponsor with a strong European presence and the ability to help us expand our operations in Asia.

“Medpace is committed to advancing the most streamlined and cost-effective path to drug approval and ultimately helping our sponsors improve people's lives. We are confident that Cinven’s investment will enable us to continue leveraging our team’s significant expertise in delivering insight, and efficiencies to every phase of a trial.”

Cinven was advised by Barclays and Wells Fargo Securities, LLC. Medpace was advised by Jefferies LLC and Fairmont Partners. Completion is subject to customary regulatory approvals.

Portfolio company videos

 Clinical Trials

Bioclinica

Clinical Trials

 Travel services provider

Hotelbeds Group

Travel services provider

 Truck component manufacturer

Jost

Truck component manufacturer

 Footwear and accessories retailer

Kurt Geiger

Footwear and accessories retailer

 Contract research organisation

Medpace

Contract research organisation

 Electronic security and alarm systems

Pronet

Electronic security and alarm systems

 Property valuation and advisory services

Tinsa

Property valuation and advisory services

 Ufinet is a neutral telecom operator.

Ufinet

Ufinet is a neutral telecom operator.

 Business services software

Visma

Business services software

Media contacts

Cinven

Vanessa Maydon
Corporate Affairs Director
Tel : +44 (0)20 7661 3325
Mob : +44 (0)7802 961 902
Email : Vanessa Maydon

Clare Bradshaw
Communications Manager
Tel : +44 (0)20 7667 3248
Mob : +44 (0)7881 918 967
Email : Clare Bradshaw

UK - FTI Consulting

Edward Bridges
Tel : +44 (0)20 7269 7147
Mob : +44 (0)7768 216 607
Email : Edward Bridges

Stephanie Ellis
Tel : +44 (0)20 3727 1173
Mob : +44 (0)7890 543 056
Email : Stephanie Ellis

France โ€“ FTI Consulting

Guillaume Granier
Tel : +33 (0)1 47 03 68 61
Mob : +33 (0)6 32 65 79 28
Email : Guillaume Granier

Caroline Guilhaume
Tel : +33 (0)1 47 03 68 17
Mob : +33 (0)6 38 91 88 51
Email : Caroline Guilhaume

Germany - FTI Consulting

Lutz Golsch
Tel : +49 (0)69 920 37 110
Mob : +49 (0)173 651 7710
Email : Lutz Golsch

Daniel Herbert
Tel : +49 (0)69 920 37 183
Mob : +49 (0)151 122 63834
Email : Daniel Herbert

US - Joele Frank

Jonathan Keehner
Tel : +1 212.355.4449
Mob : +1 917 589 2073
Email : Jonathan Keehner

Julie Oakes
Tel : +1 212.355.4449
Mob : +1 917 574 7263
Email : Julie Oakes

Spain โ€“ Groupo Albion

Alejandra Moore Mayorga
Tel : +34 91 531 23 88
Email : Alejandra Moore Mayorga

Sofia Garcia
Tel : +34 91 531 23 88

Italy โ€“ Community Group

Roberto Patriarca
Tel : +39 02 89 40 42 31
Mob : +39 335 65 09 568
Email : Roberto Patriarca

Marco Pedrazzini
Tel : +39 02 89 83 66 21
Mob : +39 347 0369 222
Email : Marco Pedrazzini